Tagged with Research

Global The global contract research organization (CRO) market is estimated to be worth USD 76.6 billion in 2023 and is projected to reach USD 127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028. Much of this growth is due to the need for novel clinical trial…

Hong Kong Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre’s mainland China arm. Yau explains how the clinical trials landscape has evolved in Hong Kong over the past five years, especially in relation to the COVID-19 pandemic. He…

Hong Kong Paul Tam, who serves as chair professor & VP at Macau University of Science and Technology as well as emeritus professor and honorary clinical professor of surgery at the University of Hong Kong, has made important contributions to advances in paediatric minimal invasive surgery, genetics, and regenerative medicine of birth…

UAE Only a small percentage of global clinical research takes place in the Middle East and Africa region today. This means that full-service MEA-focused clinical research organisation PDC CRO has a wealth of untapped opportunities to develop, according to the company’s CEO Mohamed Mostafa. He outlines PDC’s important work on COVID-19…

Belgium With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more than 20 years there, Dr Isabelle Huyghe shares the workings of the PCRU, explains how study participants are recruited, and…

Africa As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam from Leslie Sam and Associates, Jayesh Pandit, a Patient Safety Advocate from Kenya, Helen Ndagije of the Uganda National Drug…

Egypt Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do stay put – such as Roche’s Mohamed Swilam, now approaching his ninth year as general manager for Egypt – can…

UK With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from the financial havoc wreaked by the Truss administration. Despite this backdrop, activity continues in the UK’s vibrant healthcare and life…

UK “Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader of a country facing a once-in-a-generation cost of living and energy cost crisis compounded by geopolitical turbulence and the continuing…

Middle East & Africa Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa, touts the USD 1.1 trillion that its member companies have invested in R&D since 2000 and analyses the opportunities in Egypt as the country moves closer to implementing universal healthcare. In addition, he…

USA While patient groups view the United States’ new Inflation Reduction Act as a positive move towards capping out-of-pocket drug costs for older Americans, the innovative pharma industry, after aggressively lobbying against it, still argues that the new legislation will hamper drug development. [The new law] is a significant step in…

USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…